Promising efficacy data in combination with KEYTRUDA® (pembrolizumab ... Two grade three adverse events related to BT-001 were reported (one skin ulcer and one lymphocyte count decrease). No DLTs were ...

BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients. Promising efficacy ...

BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors. BT-001 in combination with KEYTRUDA® (pembrolizumab) showed promising efficacy data ...

Canker sores are small mouth ulcers that usually form on the gums. Knowing how to get rid of canker sores with home remedies and over-the-counter treatments can limit pain and discomfort. Also called ...

After proving acellular matrices are effective in treating diabetic foot ulcers, researchers are now eyeing the treatment as a tool for healing venous leg ulcers. Typically, VLU treatment includes ...

Merck’s Keytruda Combo for Urothelial Carcinoma Gets EU Approval: The European Commission granted approval to Merck’s Keytruda in combination with Astellas/Pfizer’s antibody-drug conjugate ...

Using over-the-counter NSAIDs for the occasional headache or achy back won’t typically cause a peptic ulcer. Rather, peptic ulcer disease is something that can occur with longer-term use of NSAIDs, ...

(RTTNews) - IO Biotech (IOBT) announced that the Independent Data Monitoring Committee found the data from the Pivotal Phase 3 Trial of IO102-IO103 in combination with KEYTRUDA (pembrolizumab ...

Merck MRK decided to discontinue two separate phase III studies, KEYNOTE-867 and KEYNOTE-630, evaluating its blockbuster drug Keytruda in patients with certain types of lung cancer and skin cancer ...

London: Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial ...

Mer­ck said Thurs­day morn­ing it is dis­con­tin­u­ing two Phase 3 tri­als of Keytru­da, the world’s top-sell­ing med­i­cine, af­ter in­de­pen­dent da­ta mon­i­tor­ing … ...